Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...

Japan-based Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy developed by Ionis ...

Japanese drugmaker Ono (TYO: 4528) has entered into a license agreement with USA-based Ionis Pharmaceuticals (Nasdaq: IONS) ...

Ionis Pharmaceuticals (IONS) and Ono Pharmaceutical announced that the two companies have entered into a license agreement in which Ono obtains ...

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...

Sapablursen is currently being evaluated in adults living with PV in the fully enrolled Phase 2 IMPRSSION study. Sapablursen was granted Fast Track designation and orphan drug designation in 2024 ...

Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...

Ono Pharmaceutical Co. Ltd. struck a licensing deal with Ionis Pharmaceuticals Inc. for sapablursen, which is in phase II trials for polycythemia vera. Under terms, Osaka, Japan-based Ono gains an ...

Monia, Ph.D.; “Ionis”) for sapablursen, an investigational RNA-targeted medicine for the treatment of polycythemia vera (PV). Sapablursen is currently being evaluated in adult patients with PV ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Per the deal terms, IONS will receive an upfront payment of $280 million from Ono. It is also eligible for milestone payments of up to $660 million.